Search the Newsreel

Healthcare of Ontario Pension Plan Trust Fund Lowers Stake in Beta Bionics, Inc. $BBNX

BNTX|Biontech SE|Price:92.990|Chg%:+0.540

This article provides a comprehensive stock analysis of BioNTech SE (BNTX), highlighting its healthy fundamentals and high growth potential. The stock is considered fairly valued and has high institutional ownership, with analysts rating it as a "Buy" with a price target of $127.65. Despite …

Beta Bionics Announces Second Quarter 2026 Financial Results and Updates Full Year 2026 Guidance

Beta Bionics reported net sales of $32.0 million for the second quarter of 2026, marking a 38% increase year-over-year, with strong growth in its Pharmacy Benefit Plan channel. The company initiated a pivotal trial for its iLet device in type 2 diabetes and updated …

European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union

BioNTech SE Data indicate that the 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, induces a strong immune response against contemporary circulating and emerging lineages More than five billion doses of the Pfizer-BioNTech COVID-19 vaccines distributed globally Vaccine demonstrates a favorable safety and efficacy …

Pfizer Inc. and Biontech Se Receive European Commission Authorization for 2026-2027 Xfg-Adapted Covid-19 Vaccine

Pfizer Inc. and BioNTech SE have received European Commission authorization for their 2026-2027 COVID-19 vaccine, which targets the XFG variant, for individuals aged 6 months and older. This authorization, based on an EMA recommendation, is valid across the EU, Iceland, Liechtenstein, and Norway. The …

Biontech SE (BNTX) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Biontech SE (BNTX) as of July 28, 2026. The company's current valuation score is 9.11, ranking 55th in the Biotechnology & Medical Research industry. It notes a P/E ratio of -21.06, while P/B, P/S, and P/CF data …

Bionano Genomics Inc (BNGO) Financial Health: Profitability & Balance Sheet Analysis

Bionano Genomics Inc (BNGO) has a weak financial score of 5.95, ranking 180 out of 199 in its industry due to low operating efficiency. Despite this, its latest quarterly revenue increased by 3.56% year-over-year, and net profit saw a significant 167.67% year-over-year increase. The …

Bionano Genomics Inc (BNGO) Institutional Confidence

Bionano Genomics Inc (BNGO) has an institutional shareholding score of 3.00, placing it 130th out of 199 in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion increased by 354.71% quarter-over-quarter to 10.52%. James Simons is the largest institutional shareholder, holding 0.44% of …

Beta Bionics, Inc. (BBNX) Reports Q2 Loss, Tops Revenue Estimates

Beta Bionics, Inc. (BBNX) reported a Q2 loss of $0.53 per share, exceeding the Zacks Consensus Estimate of a $0.62 loss, and revenues of $32.01 million, surpassing estimates by 2.07%. Despite outperforming earnings and revenue expectations, the company's shares have declined by 48.2% year-to-date, …

Biontech SE (BNTX) Financial Health: Profitability & Balance Sheet Analysis

This article provides an analysis of Biontech SE (BNTX)'s financial health, indicating a robust financial status but average operating efficiency. The company's financial score is 7.39, ranking it 125 out of 385 in the Biotechnology & Medical Research industry. Recent quarterly results show a …

Here's Why We're Not Too Worried About Beta Bionics' (NASDAQ:BBNX) Cash Burn Situation

Beta Bionics (NASDAQ:BBNX) has a solid cash runway of about 3.3 years, holding US$200 million in cash against an annual burn of US$61 million. Despite a slight increase in cash burn, the company's strong revenue growth of 58% and low cash burn relative to …

2 Major Reasons to Buy Moderna Stock Before July 31

Quick Read Moderna heads into Q2 earnings on a five-quarter beat streak, with traders pricing an 84% chance of another beat and a 0.12 put/call ratio. BNTX shares Moderna's ~$23B market cap but posted a 35% YoY revenue decline in Q1 while Moderna compounded …

UBS Adjusts Price Target on Beta Bionics to $22 From $24, Maintains Buy Rating

UBS has adjusted its price target for Beta Bionics (BBNX) to $22, down from $24, while maintaining a Buy rating on the stock. This update reflects a revised valuation perspective for the medical device company, which specializes in insulin delivery systems for people with …

BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit

BioNexus Gene Lab Corp. announced progress in commercializing its VitaGuard™ molecular residual disease (MRD) platform in Southeast Asia after a working visit to Tongshu Gene's facilities in China. The visit involved technical planning and meetings with Chinese hospitals where VitaGuard is already in commercial …

BioNexus Says VitaGuard Blood Tests Could Cost Under $300

BioNexus (BGLC) is progressing with the commercialization of its VitaGuard™ molecular residual disease (MRD) liquid-biopsy platform in Southeast Asia, targeting an initial rollout in select medical hubs in 2026. The company anticipates the cost per VitaGuard test to be under US$300, aiming to make …

Biontech Se Sponsored Adr (BNTXN) Q4 2022 Earnings Report - Results, Call & Slides

This article provides an in-depth report on BioNTech SE's (BNTXN) Q4 2022 earnings, highlighting that the company beat both EPS and revenue expectations. It details the actual EPS of $183.86 against a consensus of $154.43 and actual revenue of $76.15B versus expected revenue of …

Earnings To Watch: Beta Bionics Inc (BBNX) Reports Q2 2026 Result

Bionano Genomics Announces Date for Second Quarter 2026 Financial Results Conference Call and Webcast

Bionano Genomics, Inc. has announced it will host a conference call and live webcast on August 10, 2026, at 4:30 p.m. Eastern Time. The purpose of the call is to discuss the company's financial results for the second quarter of 2026 and provide updates …

Enterprise value to revenue forward of BioNTech SE Sponsored ADR – BX:22UA

This article provides a financial report indicating the enterprise value to revenue forward for BioNTech SE Sponsored ADR (BX:22UA). The report, presented by TradingView and utilizing data from ICE Data Services and FactSet, specifies a period, value, and change for this financial metric, noting …

BNGO|Bionano Genomics Inc|Price:1.075|Chg%:-0.005

This article provides a comprehensive stock analysis of Bionano Genomics Inc (BNGO) by TradingKey, detailing its financial health, valuation, earnings forecasts, price momentum, institutional confidence, and risk assessment. It highlights the company's significant growth potential, relatively stable fundamentals, and a "Buy" rating from multiple …

Bionano to Report Second Quarter 2026 Financial Results and Host a Conference Call Webcast on August 10, 2026

Bionano Genomics, Inc. (Nasdaq: BNGO) has announced that it will hold a conference call and live webcast on Monday, August 10, 2026, at 4:30 p.m. ET. The event will cover the company's financial results for the second quarter of 2026 and highlight recent corporate …

BioNexus Gene Lab Corp Revenue Breakdown – NASDAQ:BGLC

BioNexus Gene Lab Corp (NASDAQ: BGLC) revenue breakdown highlights Malaysia as the primary contributor, generating $5.83 million last year, down from $7.46 million the previous year. This information is derived from their financial statements, focusing on top segments and regional performance.

Beta Bionics Inc (BBNX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Beta Bionics Inc (BBNX) based on business segments for FY2025. The company's revenue streams are primarily from DME channel sales of iLet and single-use products, and PBP channel sales of single-use products and iLet. The data …

(BNTX) Price Dynamics and Execution-Aware Positioning

The article provides an AI-generated analysis of Biontech Se (NASDAQ: BNTX) stock, indicating weak sentiment across all time horizons and supporting a short bias. It highlights a significant 35.4:1 risk-reward short setup targeting a 10.4% downside. The analysis presents institutional trading strategies, including long, …

Biontech SE (BNTX) Cash Flow

This article provides a detailed cash flow statement for Biontech SE (BNTX), covering both annual and quarterly data across operating, investing, and financing activities. It presents key financial metrics such as operating cash flow, capital expenditures, and free cash flow, along with year-over-year percentage …

Bionano Genomics Inc (BNGO) Cash Flow

This article provides a detailed quarterly and annual cash flow statement for Bionano Genomics Inc (BNGO), allowing investors to evaluate its financial health. It includes operating, investing, and financing cash flow data, with analysis of year-over-year changes and definitions of key financial metrics. The …

BioNexus Gene Lab Corp (BGLC) Cash Flow

This article provides a detailed cash flow statement for BioNexus Gene Lab Corp (BGLC), including quarterly and annual data for operating, investing, and financing activities. It also defines key cash flow terms and offers insights into BGLC's financial health, such as an operating cash …

Bionano's Q2 Results Webcast Will Stay Online for at Least 30 Days

Bionano Genomics Inc (BNGO) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical data on dividends and stock splits for Bionano Genomics Inc (BNGO). It indicates that BNGO has not distributed any dividends in the past five years but lists several stock split events, including a 60-to-1 merger on January 22, 2025, and …

Bionano Genomics Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

This article provides a detailed profile of Bionano Genomics Inc (BNGO), a company specializing in genome analysis solutions. It outlines their business scope, including optical genome mapping (OGM) and platform-agnostic software, and provides financial data points like market capitalization and revenue breakdown. The article …

Bionano Genomics Inc (BNGO) Earnings Date & Reports & Earnings News

Bionano Genomics Inc (BNGO) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides an overview of Bionano Genomics Inc (BNGO) shareholder structure, detailing major individual and institutional holdings. It lists the top shareholders by proportion, categorizes shareholders by type, and presents a historical view of institutional shareholdings and recent changes in activity.

BioNexus Gene Lab Corp (BGLC) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of BioNexus Gene Lab Corp (BGLC), including major individual and corporate holders, their proportionate ownership, and recent activity. It also provides institutional shareholding data over several quarters, showing changes in the number of institutions and shares held. Key …

BNTX|Biontech SE|Price:89.330|Chg%:-2.730

This article provides a detailed financial overview and analyst ratings for BioNTech SE (BNTX). It highlights the company's healthy fundamentals, significant growth potential, and "Fairly Valued" status, despite a recent stock price dip and expectations for a short-term downward trend. Analysts currently rate BNTX …

Bionano Genomics, Inc. Revenue Breakdown – BMV:BNGO

Bionano Genomics, Inc. (BMV:BNGO) generated 513.94 million MXN in revenue last year. The "Consumables" segment was its top-performing segment, contributing 251.85 million MXN, though this was down from the previous year's 266.31 million MXN. Geographically, EMEA was the largest contributor, accounting for 254.34 million …

Biontech SE (BNTX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Biontech SE (BNTX), listing its major shareholders and institutional holdings as of recent reporting periods. It provides a breakdown of shareholder types and highlights significant changes in shareholdings by various entities. The article also includes related ETF …